Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Employees

129

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
26-06-29	ILA 4,316.00	+0.12%	25,109
26-06-26	ILA 4,311.00	-1.89%	59,248
26-06-25	ILA 4,394.00	+1.01%	55,275
26-06-24	ILA 4,350.00	0.00%	86,039
26-06-23	ILA 4,350.00	+0.44%	96,072

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 07:25:18 2026-06-29 EDT			5-day change	1st Jan Change
4,316.00 ^ILa	+0.12%		+0.30%	+39.01%

06-09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
05-18	Hopemark Health, Ltd announced that it expects to receive funding from BrainsWay Ltd.	CI

Market Cap	576M 0 505M 466M 436M 817M 54.35B 834M 5.6B 2.17B 26.86B 2.16B 2.12B 93.14B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	576M 0 505M 466M 436M 817M 54.35B 834M 5.6B 2.17B 26.86B 2.16B 2.12B 93.14B	EV / Sales 2026 *	8.45x	EV / Sales 2027 *	6.78x
Free-Float	90.5%	Yield 2026 *	-	Yield 2027 *	-

06-09	BrainsWay Presents First SWIFT Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	CI
05-18	Hopemark Health, Ltd announced that it expects to receive funding from BrainsWay Ltd.	CI
05-18	Brainsway announces minority-stake investment in Hopemark Health	RE
05-18	BrainsWay Takes Minority Stake in Hopemark Health	MT
05-13	BrainsWay Ltd., Q1 2026 Earnings Call, May 13, 2026
05-13	BrainsWay Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Brainsway Ltd. Reiterates Earnings Guidance for the Year 2026	CI
03-26	Brainsway Provides $6 Million Milestone-Based Convertible Loan to Neurolief	MT
03-19	Brainsway Pays $1 Million Milestone Payment to Axis Management	MT
03-18	Axis Management Company, Inc. announced that it has received $3.3 million in funding from BrainsWay Ltd.	CI
03-11	BrainsWay Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
03-11	BrainsWay Ltd., Q4 2025 Earnings Call, Mar 11, 2026
03-11	BrainsWay Ltd. Provides Earnings Guidance for Full Year 2026	CI

11-13	BrainsWay Ltd. Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder in Adolescents Aged 15 to 21	CI
25-05-14	Oppenheimer Adjusts Brainsway Price Target to $15 From $13, Maintains Outperform Rating	MT
24-05-09	Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating	MT
24-05-09	HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating	MT
23-11-16	Oppenheimer Adjusts Price Target on Brainsway to $6 From $5.50, Maintains Outperform Rating	MT

BrainsWay Ltd. Stock

Stocks

BWAY

IL0011007189

Advanced Medical Equipment & Technology

Valuation: BrainsWay Ltd.

Chart: BrainsWay Ltd.

Latest news : BrainsWay Ltd.

Last Transcript: BrainsWay Ltd.

Analysts' recommendations: BrainsWay Ltd.

Press Releases: BrainsWay Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: BrainsWay Ltd.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

07:31am	BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder	AQ
06-22	BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives	AQ
06-09	BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting	AQ
05-18	BrainsWay Announces Minority-Stake Investment in Hopemark Health	AQ
05-14	BrainsWay : Q4 2025	PU

1 day	+0.77%
1 week	+0.30%
Current month	-6.58%
1 month	-6.58%
3 months	+5.44%
6 months	+42.75%
Current year	+39.01%

1 week	4,000	4,449
1 month	3,892	4,650
Current year	3,080	5,123
1 year	1,962	5,123
3 years	386	5,123
5 years	272	5,123
10 years	272	5,123

Manager	Title	Age	Since
Hadar Levy CEO	Chief Executive Officer	54	2023-02-12
Yiftach Roth CTO	Chief Tech/Sci/R&D Officer	56	2006-04-30
Ido Marom DFI	Director of Finance/CFO	50	2023-05-22

Director	Title	Age	Since
David Zacut CHM	Chairman	74	2002-12-31
Avner Hagai BRD	Director/Board Member	70	2006-10-31
Abraham Zangen BRD	Director/Board Member	56	2019-06-16

Date	Insider	Type	Main position	Quantity	% Market Cap.
06-14	Gilead Moiseyev	Sell	Chief Technology Officer	-5,000	0.0125%
06-01	Yiftach Roth	Sell	Founder	-3,000	0.0075%
05-25	Eti Mitrany	Sell	Director	-7,980	0.0399%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BRAINSWAY LTD.	+0.12%	+0.30%	+88.71%	+992.56%	576M
THERMO FISHER SCIENTIFIC, INC.	+1.44%	+10.42%	+25.66%	+0.56%	191B
INTUITIVE SURGICAL, INC.	+1.25%	-0.51%	-24.17%	+21.54%	143B
DANAHER CORPORATION	+1.54%	+10.74%	-1.31%	-16.43%	139B
BOSTON SCIENTIFIC CORPORATION	+0.07%	-2.34%	-58.48%	-17.25%	65.74B
EDWARDS LIFESCIENCES CORPORATION	+1.18%	+3.91%	+16.07%	+0.38%	52.27B
SIEMENS HEALTHINEERS AG	+0.07%	-0.70%	-27.20%	-32.27%	43.55B
AGILENT TECHNOLOGIES, INC.	+0.37%	+7.04%	+14.13%	+16.88%	38.41B
WATERS CORPORATION	-0.66%	+5.34%	+6.24%	+45.44%	36.76B
GE HEALTHCARE TECHNOLOGIES INC.	+1.26%	+6.77%	-11.59%	-14.81%	29.91B
Average	+0.61%	+4.16%	+2.81%	+99.66%	74.01B
Weighted average by Cap.	+0.89%	+5.57%	-3.33%	+1.14%

	2026 *	2027 *
Net sales	68.15M 0 59.75M 55.08M 51.56M 96.69M 6.43B 98.7M 662M 256M 3.18B 256M 250M 11.02B	84.98M 0 74.51M 68.68M 64.3M 121M 8.02B 123M 826M 319M 3.96B 319M 312M 13.74B
Net income	13.23M 0 11.6M 10.69M 10.01M 18.77M 1.25B 19.16M 129M 49.73M 617M 49.68M 48.6M 2.14B	22.2M 0 19.47M 17.95M 16.8M 31.5M 2.09B 32.16M 216M 83.46M 1.04B 83.37M 81.55M 3.59B
Net Debt	-	-